基因编辑联盟和许可协议：2016-2024

本报告调查了 2016 年至 2024 年的基因编辑合作和许可协议，包括协议总数的趋势、财务条款和条件、活跃于协议中的主要公司的识别以及合约文件目录等。

主要优点

• 您可以瞭解 2016 年以来的合约趋势。
• 您可以查看合作伙伴关係和授权项目。
• 基准分析：您可以确定合约的市场价值
• 财务条款：一次性付款、里程碑、特许权使用费
• 合约目录：依公司名称 (A-Z)、合约类型及处理区域
• 重大合约：依合约金额
• 最活跃的合约公司
• 资产识别和每份合约的合约条款
• 取得合约文件：深入瞭解合约结构
• 尽职调查：评估拟议合约条款对合作伙伴公司的适用性
• 节省数百小时的研究时间

合约分析允许尽职调查：

• 授予或可选的具体权利有哪些？
• 合约实际上赋予了合作伙伴公司什么？
• 授予哪些类型的专有权？
• 合约的付款结构为
• 如何审核销售和付款？
• 合约期限是多久？
• 合约的主要条款是如何定义的？
• 如何对待和拥有知识产权？
• 谁负责商业化？
• 谁负责开发、供应和製造？
• 如何管理保密和发布？
• 如何解决争议
• 什么情况下可以取消合约？
• 如果所有者发生变化会怎样？
• 已就何种类型的分授权或分包条款达成协议？
• 公司需要哪些样板条款？
• 哪些样板条款看起来有所不同，取决于合作伙伴和交易类型？
• 每家公司对合约法拥有哪些管辖权？

目录

执行摘要

第一章简介

第二章 基因编辑领域的合约趋势

• 基因编辑相关合约：年度趋势
• 最活跃的基因编辑承包商
• 基因编辑相关合约：依合约类型
• 基因编辑相关合约：依治疗领域划分
• 基因编辑相关合约：依行业划分
• 基因编辑相关合约：条款与条件

第三章主要基因编辑合约

• 主要基因编辑合约：按金额

第四章 最活跃的基因编辑承包商

• 最活跃的基因编辑承包商
• 最活跃的基因编辑合约的公司简介

第五章基因编辑合约：合约目录

• 基因编辑合约：合约目录

第 6 章基因编辑合约：依技术类型划分

• 合约目录
• 合约目录：依公司分类（A-Z）
• 合约目录：依合约类型
• 合约目录：依治疗领域
• 合约类型的定义
• 关于生物製药研究股份有限公司
• 目前的合作关係
• 当前合约
• 目前合作近期报告标题

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 373 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
• Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity - 2016 - 2024
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers 2016 - 2024
• Figure 12: Gene editing deals by technology type since 2016